Clay Siegall

Dr. Clay B. Siegall is an Independent Director at Shattuck Labs, Inc., a Chairman at Tourmaline Sub, Inc. and a Chairman, President & Chief Executive Officer at Immunome, Inc. He is on the Board of Directors at Shattuck Labs, Inc., Biotechnology Innovation Organization, Life Science Washington, Washington Roundtable and The Pacific Northwest Research Institute, Inc. Dr. Siegall was previously employed as a Chairman by Tourmaline Bio, Inc., a President, Chief Executive Officer & Director by MorphImmune, Inc., a Chairman by Umoja Biopharma, Inc., an Independent Director by Nurix Therapeutics, Inc., an Independent Director by Ultragenyx Pharmaceutical, Inc., an Independent Director by Mirna Therapeutics, Inc., an Independent Director by Alder Biopharmaceuticals, Inc., a Director & Chief Scientific Officer by Seagen, Inc., and a Principal Scientist by Bristol-Myers Squibb Pharmaceutical Research Institute.
He received his undergraduate degree from the University of Maryland and a doctorate degree from George Washington University.